The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Disitamab vedotin (DV, RC48-ADC) combined with cadonilimab (anti-PD-1/CTLA-4 bispecific antibody) in patients with locally advanced or metastatic urothelial carcinoma (la/mUC): An open-label, single-arm, phase II study.
 
Wasilijiang Wahafu
No Relationships to Disclose
 
Shuqing Wei
No Relationships to Disclose
 
Xiaoyuan Qiao
No Relationships to Disclose
 
Xi Zhang
No Relationships to Disclose
 
Mingshuai Wang
No Relationships to Disclose
 
Sujun Han
No Relationships to Disclose
 
Yu Cui
No Relationships to Disclose
 
Xuebing Han
No Relationships to Disclose
 
Dongzi Pang
No Relationships to Disclose
 
Hongsong Bai
No Relationships to Disclose
 
Linjun Hu
No Relationships to Disclose
 
Zhibin Li
No Relationships to Disclose
 
Xin Wang
No Relationships to Disclose
 
Yuzhu Fan
No Relationships to Disclose
 
Nianzeng Xing
No Relationships to Disclose